The Saudi initiative for asthma – 2024 update: Guidelines for the diagnosis and management of asthma in adults and children

Author:

Al-Moamary Mohamed Saad1,Alhaider Sami A.2,Allehebi Riyad3,Idrees Majdy M.4,Zeitouni Mohammed O.5,Al Ghobain Mohammed O.1,Alanazi Abdullah F.1,Al-Harbi Adel S.6,Yousef Abdullah A.7,Alorainy Hassan S.8,Al-Hajjaj Mohamed S.9

Affiliation:

1. Department of Medicine, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia

2. Pediatrics, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

3. Department of Medicine, King Fahad Medical City, Riyadh, Saudi Arabia

4. Department of Medicine, Respiratory Division, Prince Sultan Military Medical City, Riyadh, Saudi Arabia

5. Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

6. Department of Pediatrics, Prince Sultan Military Medical City, Riyadh, Saudi Arabia

7. Department of Pediatrics, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia

8. Department of Respiratory Care, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

9. Department of Paediatrics, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates

Abstract

Abstract: The Saudi Initiative for Asthma 2024 (SINA-2024) is the sixth version of asthma guidelines for the diagnosis and management of asthma for adults and children that was developed by the SINA group, a subsidiary of the Saudi Thoracic Society. The main objective of the SINA is to have guidelines that are up-to-date, simple to understand, and easy to use by healthcare workers dealing with asthma patients. To facilitate achieving the goals of asthma management, the SINA Panel approach is mainly based on the assessment of symptom control and risk for both adults and children. The approach to asthma management is aligned for age groups: adults, adolescents, children aged 5–12 years, and children aged <5 years. SINA guidelines have focused more on personalized approaches reflecting a better understanding of disease heterogeneity with the integration of recommendations related to biologic agents, evidence-based updates on treatment, and the role of immunotherapy in management. The medication appendix has also been updated with the addition of recent evidence, new indications for existing medication, and new medications. The guidelines are constructed based on the available evidence, local literature, and the current situation at national and regional levels. There is also an emphasis on patient–doctor partnership in the management that also includes a self-management plan.

Publisher

Medknow

Subject

Cardiology and Cardiovascular Medicine,Pulmonary and Respiratory Medicine,Surgery

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3